Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (early spermatids) | 0.10 |
| chemistry Open Targets | compounds already reach it: camlipixant, gefapixant | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 38 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10240
Sealed predictions
- P2RX3 in dopamine neurons, braak+0.01 (p 0.982) → -0.33 (p 0.389)receipt 10248
Swarm cases
receipt 10248: P2RX3 in dopamine neurons, braak
- power
- full sample -0.26 (p 0.298, n 18), 95% CI -0.65 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.130, n 18). could be the mix.
- skeptic
- leave-one-out range -0.39 to -0.16, sign flips 0; without severely affected donors -0.26 (p 0.298, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for P2RX3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts